Fig. 3: CAR19 is active against pediatric ALL and adult lymphoma. | Nature Communications

Fig. 3: CAR19 is active against pediatric ALL and adult lymphoma.

From: Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Fig. 3

A ALL patients (n = 31). Horizontal bars correspond to each individual patient; bar color corresponds to type of indication (pink—ALL relapsed after HSCT, sky blue—refractory relapse, green—induction failure); blue squares represent complete remission on day 28; yellow diamonds—persistent disease on day 28; light green circle—either CRS or ICANS < / = grade 2; dark green circle—either CRS or ICANS > grade 2; orange triangle—CD19-positive relapse; red triangle—CD19-positive relapse; black cross—death. B NHL patients (n = 23). Horizontal bars correspond to each individual patient; bar color corresponds to dose level (pink—0.5 × 106 CAR-T cells/kg, blue—1.0 × 106 CAR-T cells/kg, green—1.0 × 106 CAR-T cells/kg; blue squares represent complete metabolic response determined by PET/CT scan; green squares represent partial metabolic response determined by PET/CT scan; yellow diamonds indicate refractory or persistent disease determined by PET/CT scan, light green circle represents CRS/ICANS grade ≤ 2; dark green circle represents CRS/ICANS > 2; orange triangle represents CD19-positive relapse; red triangle represents CD19-negative relapse; black cross represents death.

Back to article page